Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alvotech ALVO

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. The company's purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.


Recent & Breaking News (NDAQ:ALVO)

    Alvotech's Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland

    GlobeNewswire 2 days ago

    Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

    GlobeNewswire July 20, 2022

    Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company

    GlobeNewswire July 14, 2022

    Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®

    GlobeNewswire July 7, 2022

    Alvotech Debuts on NASDAQ First North Growth Market Becoming First Dual-Listed Icelandic Company in United States and Iceland

    GlobeNewswire June 22, 2022